Der­ma­van­t's PhI­II eczema da­ta; Ox­ford's Ni­pah vac­cine; In­ven­ti­va's €25M life­line

Der­ma­vant re­port­ed new Phase III da­ta for its atopic der­mati­tis cream Vta­ma on Thurs­day morn­ing, say­ing more than 80% of par­tic­i­pants across two stud­ies saw at least a 75% im­prove­ment in a skin-clear­ing end­point (EASI75). Ad­di­tion­al­ly, 73% of in­di­vid­u­als saw at least a two-point im­prove­ment from base­line in an­oth­er skin test (vI­GA-AD). There were no new or un­ex­pect­ed side ef­fects that arose. Vta­ma was ap­proved in May 2022 to treat plaque pso­ri­a­sis, and the sN­DA for atopic der­mati­tis is ex­pect­ed by the end of the first quar­ter. — Max Gel­man

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER